CSBio CSBio

X
[{"orgOrder":0,"company":"Ipsen","sponsor":"University of Montreal","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ipsen Enters into an Option Agreement with IRICoR and University of Montreal for A Discovery-stage Oncology Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Ipsen"},{"orgOrder":0,"company":"Sanofi","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi, MD Anderson Join Forces to Ramp up Cancer R&D","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Sanofi"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Talem Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration with Pierre Fabre","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Pierre Fabre"},{"orgOrder":0,"company":"Novadiscovery","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novadiscovery Expands Janssen Collaboration by Implementing its JINKO\u00ae Clinical Trial Simulation Platform for The Development of Lung Cancer Models","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Novadiscovery"},{"orgOrder":0,"company":"Oncodesign","sponsor":"Servier","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Servier Collaborates in The Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Oncodesign"},{"orgOrder":0,"company":"Aqemia","sponsor":"Servier","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Servier and Aqemia Extend Collaboration on Undruggable Target in Immuno-Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Aqemia"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,495.5 million","upfrontCash":"$27.1 million","newsHeadline":"Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Innate Pharma"},{"orgOrder":0,"company":"Servier","sponsor":"Aitia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aitia Enters into Multi-Year AI-Driven Drug Discovery and Drug Simulation Collaboration with Servier for Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Servier"},{"orgOrder":0,"company":"Cellectis","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$945.0 million","upfrontCash":"$105.0 million","newsHeadline":"Astrazeneca Announces Collaboration and Investment Agreement with Cellectis to Accelerate Cell Therapy and Genomic Medicine Ambitions","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Cellectis"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The alliance will combine MD Anderson’s clinical trials infrastructure and Sanofi’s pipeline of investigational treatments to lead biomarker-driven clinical studies to better understand how novel cancer drugs work.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 14, 2020

            Sanofi Company Banner

            TMF Summit 2024

            Not Confirmed

            envelop Contact Supplier

            Details:

            AstraZeneca will leverage Cellectis proprietary gene editing technologies to design novel cell and gene therapy products. Under the agreement, 25 genetic targets have been reserved for AstraZeneca, from which up to 10 candidates could be explored for development.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: AstraZeneca

            Deal Size: $945.0 million Upfront Cash: $105.0 million

            Deal Type: Collaboration November 01, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Aitia and Servier will focus to discover, validate, and strive to develop novel drug targets and candidates in pancreatic cancer by utilizating Aitia's Pancreatic Cancer Digital Twins and Servier's pre-clinical assays, therapeutic creation platforms, and expertise.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Aitia

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 17, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Sanofi is licensing a Natural Killer (NK) cell engager program for cancer targeting B7H3 from Innate’s ANKET® (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option to add up to two additional ANKET® targets.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Sanofi

            Deal Size: $1,495.5 million Upfront Cash: $27.1 million

            Deal Type: Expanded Collaboration January 25, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Aqemia has employed its unique quantum-physics-inspired artificial intelligence technology to identify innovative, patentable molecules that are experimentally active on an undruggable target in immuno-oncology.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Servier

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Expanded Collaboration January 09, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, Servier and OPM (through its OncoSNIPE program®) will be responsible for clinical research activities. Servier will fund the associated research costs. The target identification program will be funded by OPM and Servier.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Servier

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 22, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The companies will now work together to use the JINKO® platform to add layers of biological complexity to the initial disease model and then run in silico trial simulations.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration December 16, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Multi-target research collaboration leverages ImmunoPrecise’s powerful antibody discovery technologies with the long-standing expertise of Pierre Fabre in immuno-oncology.

            Lead Product(s): Antibody

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Talem Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 07, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            University of Montreal/IRICoR will conduct and finance the research program until the license is exercised. Ipsen would assume all development activities and commercialize the drug candidate globally.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: University of Montreal

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement May 04, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY